Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_04353 |
| Species: | Homo sapiens |
| Position : | chr14:97410723-97443618 |
| Year: | 2014 |
| Title: | EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | Ewing Sarcoma |
| PMID: | 25453903 |
| MONDO: | MONDO:0012817 |
| Cell Source: | 293T |
| CVCL ID: | CVCL_0063 |
| Experiment Type: | Chromatin interaction assay; Disease-associated enhancer analysis |
| High Throughput Method: | RNA-seq |
| Low Throughput Method: | 3C; RT-qPCR/qPCR; RNAi/siRNA/shRNA; Histology/immunostaining |
| Target gene : | VRK1 |
| TF name : | EWSR1 |
| Regulatory State : | Repressed |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| EWSR1 | BARD1 signaling events | pid | 29 |
| EWSR1 | TGF_beta_Receptor | netpath | 220 |
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_04352 | chr14:97410723-97443618 | NA | malignant cell | Ewing Sarcoma |